Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Albuterol, albuterol sulfate inhalation aerosol
Albuterol/salbutamol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| albuterol sulfate inhalation aerosol | DRUG | - |
Inclusion criteria: * Must be an outpatient. * Age at second visit must be birth to \<24 months old. * Parent/guardian who is willing to sign, or has signed, an informed consent. * Must have acute wheezing consistent with reversible obstructive airway disease. * Must have an asthma symptoms score b...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 27 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | tilrekimig and rHuPH20, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Albuterol/salbutamol is used to treat asthma and acute wheezing caused by obstructive airways disease. It is a small molecule inhaled therapy developed by GSK plc (ticker: GSK) and is also known as albuterol sulfate inhalation aerosol. The drug is in Phase 3 clinical development for asthma.
Albuterol/salbutamol targets ADRB2, the beta-2 adrenergic receptor. It acts as an agonist at this receptor. By activating ADRB2, the drug helps relax airway smooth muscle, which is relevant to its use in asthma and obstructive airways disease.
Albuterol/salbutamol is developed by GSK plc, which trades under the ticker GSK. GSK is the company responsible for the clinical development of this inhaled small molecule for asthma and related respiratory conditions.
Albuterol/salbutamol is in Phase 3 clinical development. It is an investigational therapy and has not been approved by the FDA for the studied indication. The Phase 3 trial has been completed, and no active trials are currently listed.
Albuterol/salbutamol has been studied in one completed Phase 3 trial, NCT00144846, titled Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children. The trial enrolled 80 participants in the United States and Puerto Rico and included both randomized and double-blind design elements.
Yes, albuterol and salbutamol are the same drug. Albuterol/salbutamol is also known as albuterol, albuterol sulfate inhalation aerosol, and albuterol/salbutamol Metered Dose Inhaler (MDI). These names refer to the same active molecule developed by GSK plc.